These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 26780287)

  • 1. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans.
    Lallukka S; Luukkonen PK; Zhou Y; Isokuortti E; Leivonen M; Juuti A; Hakkarainen A; Orho-Melander M; Lundbom N; Olkkonen VM; Lassila R; Yki-Järvinen H
    Thromb Haemost; 2017 Jan; 117(2):286-294. PubMed ID: 27929200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3.
    Lallukka S; Sevastianova K; Perttilä J; Hakkarainen A; Orho-Melander M; Lundbom N; Olkkonen VM; Yki-Järvinen H
    Diabetologia; 2013 Apr; 56(4):886-92. PubMed ID: 23334462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.
    Hyysalo J; Gopalacharyulu P; Bian H; Hyötyläinen T; Leivonen M; Jaser N; Juuti A; Honka MJ; Nuutila P; Olkkonen VM; Oresic M; Yki-Järvinen H
    Diabetes; 2014 Jan; 63(1):312-22. PubMed ID: 24009255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
    Del Ben M; Polimeni L; Brancorsini M; Di Costanzo A; D'Erasmo L; Baratta F; Loffredo L; Pastori D; Pignatelli P; Violi F; Arca M; Angelico F
    Eur J Intern Med; 2014 Jul; 25(6):566-70. PubMed ID: 24947770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
    Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.
    Isokuortti E; Zhou Y; Peltonen M; Bugianesi E; Clement K; Bonnefont-Rousselot D; Lacorte JM; Gastaldelli A; Schuppan D; Schattenberg JM; Hakkarainen A; Lundbom N; Jousilahti P; Männistö S; Keinänen-Kiukaanniemi S; Saltevo J; Anstee QM; Yki-Järvinen H
    Diabetologia; 2017 Oct; 60(10):1873-1882. PubMed ID: 28660493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue.
    Qadri S; Lallukka-Brück S; Luukkonen PK; Zhou Y; Gastaldelli A; Orho-Melander M; Sammalkorpi H; Juuti A; Penttilä AK; Perttilä J; Hakkarainen A; Lehtimäki TE; Orešič M; Hyötyläinen T; Hodson L; Olkkonen VM; Yki-Järvinen H
    Liver Int; 2020 Sep; 40(9):2128-2138. PubMed ID: 32386450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
    Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
    J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible Explanation.
    Franko A; Merkel D; Kovarova M; Hoene M; Jaghutriz BA; Heni M; Königsrainer A; Papan C; Lehr S; Häring HU; Peter A
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
    Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
    Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
    Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
    Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
    Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice.
    Matsuzaka T; Kuba M; Koyasu S; Yamamoto Y; Motomura K; Arulmozhiraja S; Ohno H; Sharma R; Shimura T; Okajima Y; Han SI; Aita Y; Mizunoe Y; Osaki Y; Iwasaki H; Yatoh S; Suzuki H; Sone H; Takeuchi Y; Yahagi N; Miyamoto T; Sekiya M; Nakagawa Y; Ema M; Takahashi S; Tokiwa H; Shimano H
    Hepatology; 2020 May; 71(5):1609-1625. PubMed ID: 31529722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
    Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
    Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.